𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Superficial bladder cancer

✍ Scribed by L. Boccon-Gibod

Publisher
Springer-Verlag
Year
1993
Tongue
English
Weight
74 KB
Volume
11
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Superficial bladder cancer
Superficial bladder cancer
✍ Harris, Jules E. ;Trybula, Marion ;King, Mary πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 711 KB

A 41-year-old white woman first noted painless hematuria at the age of 16. However, evaluation did not include cystoscopy until 7 years prior to admission, at which time a 3.5 cm diameter grade 11, noninfiltrating bladder carcinoma was noted near the right ureteral orifice. There was no known occupa

Prognostic factors in superficial bladde
Prognostic factors in superficial bladder cancer
✍ D. K. Chopin; Z. Popov; V. Ravery; J. Bellot; A. Hoznek; J. J. Patard; C. C. Abb πŸ“‚ Article πŸ“… 1993 πŸ› Springer-Verlag 🌐 English βš– 606 KB

A large body of evidence suggests that intravesical prophylaxis using bacillus Calmette-GuΓ©rin can favorably alter the natural history of superficial bladder cancer. The search for prognostic factors impacting the clinical alternative between conservative and radical treatment has been the subject o

Superficial bladder cancer: Diagnosis, s
Superficial bladder cancer: Diagnosis, surveillance and treatment
✍ Mark S. Soloway; Paul E. Perlto πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 808 KB

Approximately 70% of all bladder cancers are superficial at the time of presentation. Superficial bladder cancer includes tumors confined to the urothelium (clinical stage Ta) or lamina propria (stage T1) and flat carcinoma in situ (stage Tis). Because the biological behavior of bladder neoplasms is

Treatment of superficial bladder cancer
Treatment of superficial bladder cancer with intravesical chemotherapy
✍ Robert A. Badalament; Riad N. Farah πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 51 KB πŸ‘ 2 views

Proper care of patients with superficial bladder cancer requires the assessment of multiple factors, including an understanding of the natural history of this disease, accurate clinical staging, and the expected efficacy of each drug. The pharmacology of intravesical mytomycin C is discussed in deta